A 77-year-old male with a history of SAVR in 2011 (Magna Ease 23) and moderate chronic kidney disease, with preservedLV function, presented with symptomatic severe aortic regurgitation and stenosis, associated with severe MR.

A Sapien 3 Ultra Resilia 23 valve was implanted under local anesthesia, with hemodynamic...

An 84-year-old woman with diabetes mellitus, frailty (5/6), preserved LV function, and aortic stenosis previously treated with CoreValve 26 mm in 2016, presented with symptomatic degenerative stenosis of the valve.
A Sapien 3 (23 mm) was implanted without predilatation but with post-dilatation under general anaesthesia, using cerebral...

Join us for a LIVE case followed by a recorded case highlighting advanced treatments for severe secondary mitral regurgitation:

• A 75-year-old man with permanent AF, a history of CABG, and symptomatic severe secondary MR (atrial and ischemic causes) with low LV function (45%) underwent mitral repair with...

An 82-year-old male with a history of STEMI in 2013, stroke in 2018, cancer, and permanent AF, presented with acute heart failure with predominant right-side failure. Severe tricuspid regurgitation was identified.
The operators implanted an Evoque valve percutaneously under TEE guidance and general anaesthesia via the venous...

A 53-year-old male with a history of advanced malignancy (lung adenoma) and mid LAD PCI last year, along with multiple risk factors (hypertension, dyslipidemia, diabetes, and smoking), presented with angina and a positive stress test and CT. The angiography and CT showed significant left main stenosis...

In this interview, Chiara De Biase and Jean Marco embark on a journey through the history of interventional medicine, focusing on Charles Dotter, the pioneer of transluminal angioplasty, and Andreas Grüntzig.

In this first episode, they discuss Dotter's groundbreaking contributions, including the first interventional transluminal angioplasty in 1964, which revolutionized...

Balloon trapping or anchoring techniques, which can be challenging are explained here.

At the ESC Congress 2019 in Paris, Jean-François Obadia presented the results of the 2 years follow-Up of the MITRA-FR study. Read the report by Nicole Karam.

Dejan Milasinovic provides his take on the EVOLUT Low Risk trial, presented by Michael I. Reardon at TCT Congress 2023. 4-year results reveal a continuing trend towards lower combined rates of all-cause mortality and disabling stroke with TAVI compared with surgical aortic valve replacement (SAVR)

Nicola Ryan reviews the iFR Swedeheart multicenter, randomized, controlled, open-label clinical trial using the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) for enrolment randomisation and follow up. At one year follow up iFR guided revascularisation was shown to be non-inferior to FFR guided revascularisation, these results...

Alex Sticchi provides his take on the 5-year outcomes from PARTNER 3 Low Risk which were presented by Martin B. Leon at TCT Congress 2023.

This is a 44-year old male patient with an aortic root fistula to the right heart after past infective aortic valve endocarditis. Interventional shunt occlusion was successfully performed using a transcatheter closure device.

Panos Xaplanteris & Leonidas Koliastasis provide their take on the final results of the ECLS-SHOCK (Extracorporeal Life Support in Infarct-Related Cardiogenic Shock) which were presented by Holger Thiele during the ESC 2023 congress in Amsterdam.

Panos Xaplanteris provides his take on the results of PERFORM-TAVR presented by Jonathan Afilalo at ACC.24 in Atlanta.

Vijay Kunadian provides summaries of study designs and findings in Interventional Cardiology released at the 2021 virtual edition of the American Heart Association Congress. View an infographic of the AVATAR late-breaking trial by Ali Nazmi Calik.

Alex Sticchi provides his take on the results of the RIVER trial, which were presented by Pedro Gabriel Barros E Silva during the ESC 2023 congress in Amsterdam.

Rivaroxaban versus Warfarin in Patients with Bioprosthetic Valves According to Valvular Heart Disease Etiology, and Thrombotic and Bleeding Risks: Insights from...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that were presented for the first time during the 2024 edition of EuroPCR. These trials were selected on account of their design, outcomes and potential to influence daily clinical practice....